2012
The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis
Bari K, Miñano C, Shea M, Inayat IB, Hashem HJ, Gilles H, Heuman D, Garcia–Tsao G. The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis. Clinical Gastroenterology And Hepatology 2012, 10: 1169-1175. PMID: 22801062, PMCID: PMC3678262, DOI: 10.1016/j.cgh.2012.06.027.Peer-Reviewed Original ResearchConceptsPostparacentesis circulatory dysfunctionRecurrence of ascitesVasoconstrictor groupAlbumin groupRefractory ascitesAscites recurrenceCombination of midodrineCombination of octreotidePlacebo-controlled trialLarge-volume paracentesisEffective blood volumeTreatment of choiceSingle intravenous doseOral midodrinePreventing RecurrenceRenal failureCirculatory dysfunctionMedian timeSerum levelsIntravenous doseIntramuscular injectionIntravenous administrationAscitesMidodrineBlood volume
2011
Vasoconstrictor Therapy for Hepatorenal Syndrome
Yeo C, Garcia-Tsao G. Vasoconstrictor Therapy for Hepatorenal Syndrome. Frontiers Of Gastrointestinal Research 2011, 28: 149-162. DOI: 10.1159/000318997.Peer-Reviewed Original ResearchHepatorenal syndromeReceptor agonistClinical trialsEffective arterial blood volumeType 2 hepatorenal syndromeAlpha-adrenergic receptor agonistIschemic adverse eventsNeurohormonal system activationPreferred alternative therapyRenal function effectsFirst-line therapyMain pathogenic mechanismRandomized clinical trialsAdrenergic receptor agonistArterial blood volumeVasopressin receptor agonistSuboptimal study designEase of administrationOral midodrineRenal vasoconstrictionSystemic vasodilatationVasoconstrictor therapyDefinitive therapyIntravenous albuminKidney injury